The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.
TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.
The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.
If you have any questions you can fill in the form or mail us directly: info@train-heart.eu.
News
Review title: Non-Coding RNAs in the Therapeutic Landscape of Pathological Cardiac Hypertrophy.
Published in Cells 2022, 11(11), 1805; https://doi.org/10.3390/cells11111805
The Eschenhagen group at the University Medical Center Hamburg-Eppendorf recently published an article about the progress in the field of heart regeneration.
The research group at Lyon Unversity recently published a review to report on the many existing complex systems composed of chitosan hydrogels embedding different types of colloids used as drug delivery devices to delay the release of drugs. The various biomedical applications of such final systems are also detailed in this review.
Lead scientist Dr. Marc Hirt of University Medical Center Hamburg-Eppendorf and supervisor of Kinga Wrona (TRAIN-HEART fellow) presented his work at the Frontiers in Cardiovascular Biomedicine congress 2022
The group of Prof. Condorelli (Humanitas Hospital Milan, Italy) recently published a review on the impact of environmental factors, such as diet, smoking, and lifestyle, as pathogenic factors in heart failure development. Epigenetic changes can arise as a consequence of these factors.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 813716.
Copyright © 2020
